A Phase 2 interventional study of Psilocybin and Maltodextrin in Alcohol Use Disorder, sponsored by Anders Fink-Jensen, MD, DMSci. Completed at 1 site in Denmark. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.
Among the 17 studies testing psilocybin in Alcoholism, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 16 in phase 2, and was the 6th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–65
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Iowa · Sites in United States
Ages 21–65
University of Calgary · Sites in Canada
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2023.
This study's enrollment of 60 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
Anders Fink-Jensen, MD, DMSci is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Anders Fink-Jensen, MD, DMSci has 6 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies testing psilocybin in Alcoholism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05995769University of CalgaryPsilocybin-Assisted Psychotherapy for Alcohol Use Disorder | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing psilocybin in Alcoholism, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Note: The trial is only eligible for citizens of Denmark.
The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
To establish efficacy, we will investigate a single dose of psilocybin versus placebo in a randomised, double-blinded, placebo-controlled 12 weeks clinical trial. 90 patients, aged 20-70 years, diagnosed with alcohol use disorder and treatment seeking will be recruited from the community via advertisement and referrals from general practitioners and hospital units. The psilocybin or placebo is administered within a protocol of psychological support before, during and after the dosing. Outcome assessments will be carried out one, four, eight- and 12 weeks post dosing. The primary outcome is reduction in the percentage of heavy drinking days from baseline to follow-up at 12 weeks. Key secondary outcomes include 1) phosphatidyl-ethanol as an objective biomarker for alcohol consumption 2) plasma psilocin, the active metabolite, to establish a possible therapeutic range and 3) the acute subjective drug experience as a possible predictor of treatment outcome. Furthermore, we will investigate the neurobiological underpinnings of the possible treatment effects by use of functional magnetic resonance brain imaging one week post dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45 patients will receive a single administration of 25mg psilocybin given in a protocol of psychological support before, during and after dosing.
Drug: Psilocybin
45 patients will receive a single administration of placebo (lactose) given in a protocol of psychological support before, during and after dosing.
Drug: Maltodextrin
Psilocybin-assisted therapy
Placebo-assisted therapy
Change in percentage of heavy drinking days
Heavy drinking is defined as days with five drinks/60 grams of alcohol or more for men, four drinks/48 grams of alcohol or more for women. Data will be collected using the Timeline Followback Method (TLFB) which is a widely used, calendar-based retrospective measure of self-reported use of alcohol. The number of days drinking assessed is 28 days.
Time frame: Baseline to week 12
Change in total alcohol consumption
Total grams of alcohol consumed per day as measured by TLFB.
Time frame: Baseline to week 12
Change in days of abstinence
Percentage of days without any alcohol consumption as measured by TLFB.
Time frame: Baseline to week 12
Change in phosphatidyl-ethanol (PEth)
PEth is formed only in the presence of alcohol and is correlated with the amount of alcohol consumed the past month. PEth concentrations will be measured by peripheral blood test.
Time frame: Baseline to week 12
Change in Alcohol Use Disorders Identification Test (AUDIT)
AUDIT is a 10-item questionnaire that measures alcohol use. The score range is 0-40, with higher scores indicating a more problematic use of alcohol.
Time frame: Baseline to week 12
Change in Penn Alcohol Craving Scale (PACS) score
PACS is a 40-item questionnaire that measures alcohol craving severity. The score range is 0-30, with higher scores indicating more severe symptoms.
Time frame: Baseline to week 12
Change in Alcohol Abstinence Self-efficacy Scale (AASE) score
AASE is a 40-item questionnaire that measures two scales: the temptation to drink and the confidence in the ability to avoid drinking. The score range for each scale is 0-80, with higher score indicating greater temptation or confidence, respectively.
Time frame: Baseline to week 12
Change in Fagerstrom Test for Nicotine Dependence (FTND)
FTND is a 6-item questionnaire that measures the quantity of cigarette consumption, the compulsion to use, and dependence. The score range is 0-10, with higher scores indicating a more severe dependence.
Time frame: Baseline to week 12
Change in Drug Use Disorders Identification Test (DUDIT)
DUDIT is an 11-item questionnaire that measures drug use. The score range is 0-44, with higher scores indication a more problematic use.
Time frame: Baseline to week 12
Change in Major Depression Inventory (MDI)
MDI is a 12-item questionnaire that measures depression severity. The score range is 0-50, with higher scores indicating greater severity.
Time frame: Baseline to week 12
Change in Short-Form 36 (SF-36)
SF-36 is a 36-item questionnaire that measures the quality-of-life. The score range is 0-100, with higher scores indicating better health status.
Time frame: Baseline to week 12
Change in Mindful Attention Awareness Scale (MAAS)
MAAS is a 15-item scale that measures core characteristic of mindfulness. The score range is 1-6, with higher scores indicating greater mindfulness.
Time frame: Baseline to week 12
Change in Acceptance and Action Questionnaire (AAQ)
AAQ is a 7-item questionnaire that measures psychological flexibility. The score range is 7-49, with higher scores indicating lesser flexibility.
Time frame: Baseline to week 12
Change in NEO-Personality Inventory (NEO-PI=
The NEO-PI is a 240-item personality instrument that measures the five factors in the Five Factor Model. It consists of 30 eight-item facet scales, 6 for each of the five basic personality factors: Neuroticism (N), Extraversion (E), Openness (O), Agreeableness (A), and Conscientiousness (C), rated by use of a 5-point Likert-type scale ranging from strongly disagree to strongly agree.
Time frame: Baseline to week 12
Persisting Effects Questionnaire (PEQ)
PEQ is a 143-item scale aiming to assess changes in attitudes, moods, behavior, and spiritual experience
Time frame: Week 12
Neuroplasticity and inflammation
Neuroplasticity and inflammation as measured by mean concentrations of plasma serum brain-derived neurotrophic factor (BDNF) and plasma cytokines, respectively.
Time frame: Baseline to week 12
Subjective effects of psilocybin: Subjective Drug Intensity (SDI)
SDI will be regularly assessed asking the patients "how intense is the experience right now" on a 0-10 Likert scale where 0 = not intense at all, 10 = very intense.
Time frame: 0-6 hours post dosing
Pharmacokinetics- and dynamics of psilocybin
Pharmacokinetics- and dynamics of plasma psilocin, serum BDNF and plasma cytokines, as determined by concentration-time curves of mean plasma concentrations
Time frame: 0 - 6 hours post dosing
Subjective effects of psilocybin: Mystical Experience Questionnaire (MEQ)
MEQ is a 30-item questionnaire that measures experiential aspects of psilocybin. The patients are asked to rate the items on a 6-point scale going from 0= none; not at all to 5=extreme; more than ever before in my life and stronger than 4.
Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing
Subjective effects of psilocybin: 5-Dimensional Altered State of Consciousness scale (5D-ASC)
5D-ASC is a 94-item questionnaire that measures experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).
Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing
Subjective effects of psilocybin: Ego Dissolution Inventory (EDI)
EDI is a 8-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).
Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing
Subjective effects of psilocybin: Emotional Breakthrough Inventory (EBI)
EBI is a 6-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items by placing marks on a horizontal visual analogue scale (100 millimeters in length) going from "no, not more than usual" (on the left) to "yes, very much more than usual" (on the right).
Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing
Subjective effects of psilocybin: Awe Experience Scale (AWE-S)
AWE-S is a 30-item questionnaire that measures the experiential aspects of psilocybin. The patients are asked to rate the items on a 7-point scale going from 1= Strongly Disagree to 7= Strongly Agree.
Time frame: Completed once the effects are fully subsided or at least 6 hours after dosing
Brain imaging
The blood-oxygen-level-dependent differences between the two treatment arms with respect to resting-state functional connectivity, alcohol vs neutral cue-reactivity within mesocorticolimbic pathways and habitual vs goal-directed activity within corticostriatal pathways
Time frame: 1 week post dosing
Role of the Music I
We will explore the role of the music in psilocybin-assisted therapy by use of the questionnaires Experience with Music and Geneva Emotional Music Scale
Time frame: before and after dosing
Role of the Music II
We will explore the role of the music in psilocybin-assisted therapy by qualitative semi-structured interview
Time frame: week 4
Treatment expectancies
The Stanford Expectations of Treatment Scale is a 6 item a scale that measures positive and negative treatment expectancies using a Likert scale from 1 (strongly disagree) to 7 (strongly agree)
Time frame: Baseline
Optional long-term follow-ups
Patients may consent to post-trial follow-up to explore the long-term effects on drinking outcomes using TLFB adjusted for current or previous treatments since completing the trial.
Time frame: week 26 and week 52
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Immediately following publication. No end date.
Access criteria: Researchers who provide a methodologically sound proposal.
Ran from Sep 2023 to primary completion in Dec 2025, 27 months.
Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's 27 months is below that.
Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Anders Fink-Jensen, MD, DMSci